

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest  
and a Waiver under 18 U.S.C. §208(b)(3)

**Karl Kiebertz, M.D.**

**Committee:** Peripheral and Central Nervous System Drugs Advisory Committee

**Meeting Date:** May 17, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to supplemental new drug application (NDA) 20823, SE1-016, Exelon® (rivastigmine tartarate) Capsules (1.5 milligrams (mg), 3.0 mg, 4.5 mg, and 6.0 mg), sponsored by Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG, for the proposed indication of the treatment of mild to moderate dementia associated with Parkinson’s disease, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

<b>Type of Interest</b>	<b>Nature</b>	<b>Magnitude</b>
Unrelated Steering Committee Membership	Sponsor	Less than \$10,001
Unrelated Data Safety Monitoring Board Membership	Competitor	Less than \$10,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

\_\_\_\_\_/s/\_\_\_\_\_  
Signature of SGE

\_\_\_\_\_/4/06/06\_\_\_\_\_  
Date